IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in bullous pemphigoid: Serum levels of these immunoglobulins reflect disease activity

Journal of the American Academy of Dermatology

Volumn 42, Issue 4, 2000, Pages 577-583

  Döpp, Rebekka ^a   Schmidt, Enno ^a   Chimanovitch, Iakov ^a   Leverkus, Martin ^a   Bröcker, Eva B ^a   Zillikens, Detlef ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4;

ARTICLE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMIDESMOSOME; HUMAN; IMMUNOBLOTTING; IMMUNOGLOBULIN BLOOD LEVEL; MALE; NONHUMAN; PEMPHIGOID; PRIORITY JOURNAL; PROTEIN DOMAIN; REMISSION;

EID: 0033926986     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2000.103986     Document Type: Article

References (37)

1. Zillikens D. Acquired skin disease of hemidesmosomes. J Dermatol Sci 1999;20:134-54.
2. Stanley JR, Hawley-Nelson P, Yuspa SH, Shevach EM, Katz SI. Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia. Cell 1981;24:897-903.
3. Stanley JR, Tanaka T, Mueller S, Klaus-Kovtun V, Roop D. Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies. J Clin Invest 1988;82:1864-70.
4. Diaz LA, Ratrie III H, Saunders WS, Futamura S, Squiquera HL, Anhalt GJ, et al. Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera: immunolocalization of this protein to the hemidesmosome. J Clin Invest 1990;86:1088-94.
5. Giudice GJ, Emery DE, Diaz LA. Cloning and primary structural analysis of the bullous pemphigoid autoantigen, BP 180. J Invest Dermatol 1992;99:243-50.
6. Tanaka T, Korman NJ, Shimizu H, Eady RAJ, Klaus-Kovtun V, Cehrs K, et al. Production of rabbit antibodies against carboxy-terminal epitopes encoded by bullous pemphigoid cDNA. J Invest Dermatol 1990;94:617-23.
7. Zillikens D, Giudice GJ. BP180/type XVII collagen: its role in acquired and inherited disorders of the dermal-epidermal junction. Arch Dermatol Res 1999;291:187-94.
8. Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Giudice GJ. A passive transfer model of the organ specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993;92:2480-8.
9. Zillikens D, Rose PA, Balding SD, Liu Z, Olague-Marchan M, Diaz LA. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J Invest Dermatol 1997;109:573-9.
10. Zillikens D, Mascaro JM, Rose PA, Liu Z, Ewing SM, Caux F, et al. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol 1997;109:679-83.
11. Schmidt E, Obe K, Bröcker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease acitivity in patients with bullous pemphigoid. Arch Dermatol In press.
12. Hornschuh B, Hamm H, Wever S, Hashimoto T, Schroder U, Bröcker EB, et al. Treatment of 16 patients with bullous pemphigoid with oral tetracycline and niacinamide and topical clobetasol. J Am Acad Dermatol 1997;36:101-3.
13. Chimanovitch I, Schmidt E, Messer G, Döpp R, Partsch K, Bröcker EB, Zillikens D. IgG1 and IgG3 are the major immunoglobulin subclasses targeting epitopes within the NC16A domain of BP180 in pemphigoid gestationis. J Invest Dermatol 1999; 113:140-2.
14. Bird P, Friedmann PS, Ling N, Bird AG, Thompson RA. Subclass distribution of IgG antibodies in bullous pemphigoid. J Invest Dermatol 1986;86:21-5.
15. Yamada H, Hashimoto T, Nishikawa T. IgG subclasses of intercellular and basement membrane zone antibodies: the relationship to the capability of complement fixation. J Invest Dermatol 1989;92:585-7.
16. Brooks WS, Lee YY, Abell E, Deng JS. Comparison of subclasses and complement binding activity of autoantibodies from patients with bullous pemphigoid and pemphigus. J Clin Lab Anal 1989;3:307-11.
17. Bernard P, Prost C, Aucouturier P, Durepaire N, Denis F, Bonnetblanc JM, et al. Immunoblot analysis of IgG subclasses of circulating antibodies in bullous pemphigoid. Clin Immunol Immunopathol 1990;54:484-94.
18. Suzuki M, Harada S, Kanazawa K, Kitajima Y, Yaoita H. Relationship between antigens and IgG subclasses in bullous pemphigoid. Autoimmunity 1994;18:217-25.
19. Egan CA, Taylor TB, Meyer LJ, Petersen MJ, Zone JJ. Bullous pemphigoid sera that contain antibodies to BPAg2 also contain antibodies to LABD97 that recognize epitopes distal to the NC16A domain. J Invest Dermatol 1999;112:148-52.
20. Nie Z, Hashimoto T. IgA antibodies of cicatricial pemphigoid sera specifically react with the C-terminus of BP180. J Invest Dermatol 1999;112:254-5.
21. Perriard J, Jaunin F, Favre B, Büdinger L, Hertl M, Saurat JH, et al. IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and the intracellular domains of the BP antigen 180. J Invest Dermatol 1999; 112:141-7.
22. Dahl MV. Clinical immunodermatology. St Louis: Mosby; 1996. p. 19-24.
23. Gammon WR, Merritt CC, Lewis DM, Sams WM, Carlo R, Wheeler CE. An in vitro model of immune complex-mediated basement membrane zone separation caused by pemphigoid antibodies, leukocytes and complement. J Invest Dermatol 1982;78:285-90.
24. Liu Z, Giudice GJ, Swarz SJ, Fairley JA, Till GO, Troy JL, et al. The role of complement in experimental bullous pemphigoid. J Clin Invest 1995;95:1539-44.
25. Provost TT, Tomasi B Jr. Evidence for complement activation via the alternate pathway in skin diseases I. Herpes gestationis, systemic lupus erythematosus, bullous pemphigoid. J Clin Invest 1973;52:1779-87.
26. Jordon RE, Kawana S, Fritz KA. Immunopathologic mechanisms in pemphigus and bullous pemphigoid. J Invest Dermatol 1985;85(Suppl):72s-78s.
27. Zillikens D, Caux F, Mascaro JM, Wesselmann U, Schmidt E, Prost C, et al. Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180. J Invest Dermatol 1999;113:127-31.
28. Parodi A, Rebora A. Serum IgE antibodies bind to the epidermal side of the basement membrane zone splits in bullous pemphigoid. Br J Dermatol 1992;126:526-7.
29. Soh H, Hosokawa H, Asada Y. IgE and its related phenomena in bullous pemphigoid. Br J Dermatol 1993;128:371-7.
30. Delaporte E, Dubost-Brama A, Ghohestani R, Nicolas JF, Neyrinck JL, Bergoend H, et al. IgE autoantibodies directed against the major bullous pemphigoid antigen in patients with a severe form of pemphigoid. J Immunol 1996;157:3642-7.
31. Ghohestani RF, Cozzani E, Delaporte E, Nicolas JF, Parodi A, Claudy A, et al. IgE antibodies in sera from patients with bullous pemphigoid are autoantibodies preferentially directed against the 230-kDa epidermal antigen (BP230). J Clin Immunol 1998;18:202-9.
32. McKenzie GJ, Bancroft A, Grencis RK, McKenzie AN. A distinct role for interleukin-13 inTh2-cell-mediated immune responses. Curr Biol 1998;12:339-42.
33. de Vries JE, Carballido JM, Aversa G. Receptors and cytokines involved in allergic TH2 cell responses. J Allergy Clin Immunol 1999;103:492-6.
34. Schmidt E, Bröcker EB, Zillikens D. High levels of soluble CD23 in blister fluid of patients with bullous pemphigoid. Arch Dermatol 1995;131:966-7.
35. Schmidt E, Bastian B, Dummer R, Tony HP, Bröcker EB, Zillikens D. Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. Arch Dermatol Res 1996;288:353-7.
36. Büdinger L, Borradori L, Yee C, Eming R, Ferencik S, Grosse-Wilde H, et al. Identification and characterization of autoreactiveT cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest 1998;102:2082-9.
37. Hirako Y, Usukura J, Nishizawa Y, Owaribe K. Demonstration of the molecular shape of BP180, a 180-kDa bullous pemphigoid antigen and its potential for trimer formation. J Biol Chem 1996;271:13739-45.